William Blair analyst Matt Phipps reiterated a Buy rating on Biogen (BIIB – Research Report) on June 15. The company’s shares closed last Friday at $388.44.
According to TipRanks.com, Phipps is a 3-star analyst with an average return of 5.7% and a 49.4% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Autolus Therapeutics.
Biogen has an analyst consensus of Moderate Buy, with a price target consensus of $428.09, which is a 10.6% upside from current levels. In a report issued on June 3, Jefferies also assigned a Buy rating to the stock with a $450.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $468.55 and a one-year low of $223.25. Currently, Biogen has an average volume of 1.7M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis.
